Key references: Periprocedural management of adults with type 2 diabetes
Australian Diabetes Society (ADS). Alert update January 2022 - Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor Use In People with Diabetes. Sydney: ADS; 2022. https://diabetessociety.com.au/position-statements.asp
Diabetes Canada Clinical Practice Guidelines Expert Committee, Malcolm J, Halperin I, Miller DB, Moore S, Nerenberg KA, et al. In-hospital management of diabetes. Can J Diabetes 2018;42 Suppl 1:S115–S23. https://www.ncbi.nlm.nih.gov/pubmed/29650083
Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. J Clin Endocrinol Metab 2019;104(8):3077-87. https://www.ncbi.nlm.nih.gov/pubmed/30835263
Hamblin PS, Wong R, Ekinci EI, Sztal-Mazer S, Balachandran S, Frydman A, et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor-Treated Type 2 Diabetes. Diabetes Care 2021. https://www.ncbi.nlm.nih.gov/pubmed/33896795
Meyer EJ, Mignone E, Hade A, Thiruvenkatarajan V, Bryant RV, Jesudason D. Periprocedural Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy. Diabetes Care 2020;43(11):e181-e4. https://www.ncbi.nlm.nih.gov/pubmed/32943440
